Page 3 | Certara

Announcement

Certara Enables Discovery Scientists to Accelerate Therapeutic Peptide Discovery with New D360 version

Discover how D360 26.0 enhances peptide design, sequence analysis, and workflows to help scientists accelerate…

CertaraApril 23, 2026

Blog

Top 10 Benefits of Simcyp® Simulator for Drug Development

JTVCdGVhbV9qdW1wX2xpc3QlNUQ= April 23, 2026 Physiologically based pharmacokinetic (PBPK) modeling has evolved from an emerging methodology…

CertaraApril 23, 2026

Blog

ADC Dose Optimization: Applying Model-Informed Strategies in Development

Explore ADC dose optimization using model-informed strategies to balance efficacy and safety across antibody drug…

CertaraApril 22, 2026

Video

Certara Talks – Pivotal Trial Mandate

Explore how the FDA’s shift toward one pivotal trial plus supporting evidence could reshape drug…

CertaraApril 22, 2026

Press Release

Certara Enters Definitive Agreement for the Sale of its Regulatory Writing and Medical Writing Business to Veristat

Transaction sharpens focus on Model-Informed Drug Development (MIDD) and Clinical Intelligence Updated 2026 guidance to…

CertaraApril 22, 2026

Fact Sheet

BaseCase® Turn Evidence into Decisions – at Scale

BaseCase value communication software transforms complex economic models and clinical data into interactive, field-ready tools.

Danielle PillsburyApril 21, 2026

Blog

FDA ESG Integration: Why Now Is the Time to Move Beyond Manual Submissions

Discover how FDA Electronic Submissions Gateway (ESG) integration reduces manual work, improves compliance, and accelerates…

CertaraApril 20, 2026

Video

Modeling Hope: From Patient to Scientist Ellen Swanson on QSP, Breast Cancer, and Hope Through Science

Ellen Swanson, QSP Senior Scientist at Certara, shares her personal journey from breast cancer diagnosis…

CertaraApril 16, 2026

Fact Sheet

ToxStudio® Predictive Toxicology Software

Learn about ToxStudio: Predictive toxicology software to support prediction of drug-induced liver injury (DILI), QT…

CertaraApril 16, 2026

Blog Knowledge Base

Mean Residence Time (MRT): Understanding How Long Drug Molecules Stay in the Body

JTVCdGVhbV9qdW1wX2xpc3QlNUQ= April 16, 2026 When I first began learning about pharmacokinetics (PK), I was often…

CertaraApril 16, 2026

Certara Enables Discovery Scientists to Accelerate Therapeutic Peptide Discovery with New D360 version

Top 10 Benefits of Simcyp® Simulator for Drug Development

ADC Dose Optimization: Applying Model-Informed Strategies in Development

Certara Talks – Pivotal Trial Mandate

Certara Enters Definitive Agreement for the Sale of its Regulatory Writing and Medical Writing Business to Veristat

BaseCase® Turn Evidence into Decisions – at Scale

FDA ESG Integration: Why Now Is the Time to Move Beyond Manual Submissions

Modeling Hope: From Patient to Scientist Ellen Swanson on QSP, Breast Cancer, and Hope Through Science

ToxStudio® Predictive Toxicology Software

Mean Residence Time (MRT): Understanding How Long Drug Molecules Stay in the Body

Newsletter sign up

Quick links

Solutions

Contact